Clearside Biomedical, Inc.

The momentum for this stock is not very good. Clearside Biomedical, Inc. is not a good value stock. Clearside Biomedical, Inc. is a mediocre stock to choose.

Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the devel...

News

Clearside Biomedical, Inc. (NASDAQ:CLSD) Receives Average Recommendation of "Buy" from Analysts

Ticker Report Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) have earned a consensus rating of "Buy" from the six brokerages that are covering the company, MarketBeat reports. Six equities...\n more…

HC Wainwright Reiterates Buy Rating for Clearside Biomedical (NASDAQ:CLSD)

Zolmax Clearside Biomedical (NASDAQ:CLSD - Get Free Report)s stock had its "buy" rating reissued by investment analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They...\n more…

Clearside Biomedical management to meet with Oppenheimer

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Optimistic Buy Rating for Clearside Biomedical Amid Promising ODYSSEY Trial Results and Strong Financial Position

TipRanks Financial Blog JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on CLSD stock, giving a Buy rating on August 21. Debanjana Chatterjee...\n more…

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Globe Newswire - CLS-AX is a Highly Potent Tyrosine Kinase Inhibitor Delivered Suprachoroidally Using Clearside's Proprietary SCS Microinjector - - Topline Data Expected to be Reported During the Week of...\n more…